Chris Wigley 2026 Distinguished Alumni

Dr. Chris Wigley is Senior Vice President, Chief Scientific Officer, and a founding scientist at Reata Pharmaceuticals. Throughout his career, Dr. Wigley has played a central role in advancing groundbreaking therapeutic research from concept to clinical reality.

Dr. Wigley helped lead the development of Skyclarys®, the first and only FDA-approved treatment for Friedreich’s ataxia, a rare, progressive neuromuscular disease that significantly affects children and families.

Under Dr. Wigley’s scientific leadership, Reata Pharmaceuticals established itself as a leader in innovative drug development targeting serious and underserved diseases. The company was recently acquired by Biogen, a global biotechnology leader, to further develop and expand access to Skyclarys® and related therapies, highlighting the work Dr. Wigley helped pioneer. 

Dr. Wigley has demonstrated a commitment to scientific excellence, collaboration, and patient-focused innovation. His contributions stand as a testament to the far-reaching impact of research and discovery, and reflect the values of service, perseverance, and innovation fostered within the Texas Tech University College of Arts & Sciences.  

Education

BA Biochemistry, 1988 
Ph.D. Chemistry, 1992